pdufa date
[SAMPLE DATA] FDA PDUFA target action date for HLX-201, Helixara's investigational mRNA therapy for rare metabolic disorders.
searchable onlyConfidence: confirmed
Catavist surfaces factual summaries of public clinical trial events, FDA calendar milestones, and regulatory readouts — sourced from ClinicalTrials.gov, SEC/EDGAR filings, and public press releases. Structured monitoring for researchers and investors who need clarity, not hype.
Catavist provides informational monitoring and research — not financial advice. All content is derived from public sources and is intended for research purposes only.
A sample of recently published public catalyst summaries.
See the next wave of public biotech catalyst dates.
| Date | Ticker | Event Type | Headline | Signal |
|---|---|---|---|---|
| May 14, 2026 | HLXFAKE Helixara Therapeutics Inc. | pdufa date | [SAMPLE DATA] FDA PDUFA target action date for HLX-201, Helixara's investigational mRNA therapy for rare metabolic disorders. | searchable only |
| Jun 9, 2026 | ONCVFAKE Oncovant BioSciences Ltd. | phase3 readout | [SAMPLE DATA] Phase 3 top-line results expected for OCV-440 in treatment-resistant non-small cell lung cancer. | searchable only |
| Jul 22, 2026 | NPLXFAKE Novaplex Gene Therapy Corp. | nda submission | [SAMPLE DATA] BLA submission anticipated for NPX-7 gene therapy targeting inherited retinal dystrophy. |
Get weekly catalyst updates
Join the weekly digest for notable public biotech catalyst updates. This is an email newsletter signup only and does not create a Catavist account or promise immediate paid alerts.
| searchable only |